Introduction

▼
In 1989 vascular endothelial growth factor (VEGF) was identifi ed as an angiogenic factor [ 1 ] . VEGF is a potent stimulator of endothelial cell growth and a critical regulator of both physiological and pathological angiogenesis [ 2 ] . VEGF binds to 2 diff erent tyrosine kinase receptors VEGFR-1 (fl t-1) and VEGFR-2 (fl k-1/KDR), mainly expressed on endothelial cells [ 3 ] . VEGFR-1 may play a more regulatory role in an giogenesis, whereas VEGFR-2 is responsible for signaling [ 4 ] . In addition, VEGF mediates infl ammatory reactions [ 5 ] . Via a paracrine mechanism VEGF signaling plays a critical role in tumor angiogenesis, hence, high expression of VEGF and its receptors was shown in a number of human cancers such as gastric cancer [ 6 ] , breast cancer [ 7 ] , colon cancer [ 8 ] , ovarian cancer [ 9 ] and prostate cancer [ 10 ] . Increased expression of VEGF was even linked to poor outcome and increased risk for metastasis To date, the role and expression of VEGF and its receptors in normal and benign diseases of the thyroid have rarely been investigated. This study was performed to investigate the expression pattern of VEGF and its receptors in thyrocytes from normal thyroid tissue and benign thyroid diseases.
Materials and Methods
▼
Patients 50 patients (♀ = 38, ♂ = 12) were enrolled in the clinical study. The protocol was approved by the ethics committee of the University Hospital of Frankfurt and preoperative written consent was obtained from all patients. The patients were divided into 4 groups according to the diagnosis, 11 patients with uninodular goiter (UN), 15 with multinodular goiter (MN), 10 with Graves' disease (G) and 14 patients with recurrent nodular goiter (R) were operated on and included. Recurrent goiter was defi ned as development or regrowth of nodules after the fi rst operation of the thyroid gland as revealed by the patient's history. The indication for reoperation was one or more nodular growths as detected by ultrasound. All patients fulfi lled these criteria.
Tissue samples and cell culture
Thyroid tissue was obtained after surgical resection. All tissue samples were examined and characterized by a pathologist and when possible, nodular and adjacent non-tumor or paranodular tissues were acquired. In the case of Graves' disease only paranodular tissue was investigated. The thyroid tissue was minced into small fragments, washed 3 times with HBSS (Hank's balanced salt solution) containing 50 U/ml penicillin and 50 μg/ml streptomycin followed by enzymatic dissociation with 246 U/ml collagenase I for 60-90 min at 37 °C. After digestion, thyrocytes were fi ltered through a 100 μm nylon mesh (Becton Dickinson; Heidelberg, Germany), pelleted and washed with HBSS. Thyrocytes were resuspended and counted in Neubauer counting chamber before plating. Cell viability was assessed using trypan blue exclusion ( > 98 %). Thyrocytes were plated at a density of 50 000 cells/well in 6-well plates and were cultured in DMEM supplemented with 10 % fetal calf serum, 200 mM Hepes, 50 U/ml penicillin and 50 μg/ml streptomycin. The monocultures were maintained in a standard humidifi ed incubator at 37 °C in a 5 % CO 2 atmosphere. On day 1 medium was changed to remove cell debris, on day 4 harvesting was performed. Thyrocyte culture by this procedure has no detectable stromal or endothelial contamination, as attested to by immunohistochemistry and PCR.
Immunofl uorescence
Primary thyrocyte cultures were washed with PBS (phosphate buff ered saline) and fi xed with ice cold acetone for 10 min. After fi xation, cells were washed again followed by incubation with primary antibody for 60 min at 4 °C. Primary antibodies were as follows: mouse monoclonal anti-cytokeratine 18 (clone Ks18.04) and 19 (clone Ks19.10) (Progen Biotechnik; Heidelberg, Germany, diluted 1:2), mouse monoclonal anti-fi broblast antibody (Acris antibodies; Hiddenhausen, Germany, diluted 1:100), mouse anti-von Willebrand factor (Dako; Hamburg, Germany, diluted 1:50). After incubation with primary antibodies, cultures were washed twice with wash buff er (0.5 % BSA in PBS without Ca + + and Mg + + ) followed by incubation with secondary antibody for 60 min at 4 °C (NL493 [NorthernLights] -conjugated donkey anti-mouse IgG, diluted to 1:100, (R&D Systems; Wiesbaden-Nordenstadt, Germany). All antibodies were diluted with 0.5 % BSA (bovine serum albumin) in PBS. Cell cultures were rinsed 3 times in wash buff er and fi nally mounted with Prolong antifade Kit (Molecular Probes; Eugene, Oregon). Staining was visualized microscopically by Zeiss Z-1 Observer (Zeiss; Göttin-gen, Germany). A negative control was also carried by incubating cell cultures with mouse IgG1 (Dako Cytomation, Denmark). All controls were consistently negative.
RNA isolation, cDNA synthesis, semiquantitative RT-PCR, quantitative PCR
Total RNA was extracted using RNeasy kit (Qiagen GmbH; Hilden, Germany) according to the manufacturer's instructions. cDNA was synthesized from 1 μg of total RNA with Oligo (dT) Primer using Affi nityScript QPCR cDNA synthesis kit (Stratagene; CA, USA) according to the manufacturer's instructions. Thyroid peroxidase (TPO), TSH receptor (TSHR), Thyreoglobulin (Tg), VEGF-A and VEGFR-1 and -2 transcripts were analyzed by performing reverse-transcriptase PCR (RT-PCR) ( • ▶ Table 1 ). RNA amount and RNA quality were analyzed using Nanovue (GE Healthcare, USA) and Bioanalyzer (Agilent Technologies, USA) respectively. Semi-quantitative RT-PCR was carried out in a 50 μl reaction mixture for each assay containing 1 μl of DNA template, 5 μl of 10 × Titanium Taq PCR Buff er, 1 μl of 50 × Titanium Taq DNA polymerase (Takara Bio Europe/Clontech; Saint Germainen-Laye, France), 1 μl of dNTPs (10 mM of each dATP, dCTP, dGTP, dTTP from Takara Bio Europe/Clontech) and 1 μl of primer mix -50 pmol, of each forward and reverse primer ( • ▶ Table 1 ) using a Tpersonal Thermocycler (Biometra GmbH; Goettingen, Germany). PCR parameters were as follows: initial denaturation at 95 °C for 5 min followed by 35 cycles 30 s denaturation at 95 °C; 30 s of annealing at 64 °C for VEGF-A, VEGFR-1, and VEGFR-2, 58 °C for GAPDH and 55 °C for TPO, TSHR and Tg; 30 s elongation at 72 °C and, fi nally, a further elongation step at 72 °C for 10 min. Ethidium bromide stained amplifi ed fragments were separated by agarose gel electrophoresis (2 %), visualized and analyzed by Gel Doc 100 with molecular analyst software (BioRad Laboratories; Munich, Germany). Densitometric analysis was performed and signal was evaluated as area (mm 2 ). GAPDH was used as housekeeping gene and a 100 bp DNA ladder was used as molecular weight marker. The results were confi rmed by real-time quantitative PCR (QPCR) using RT² SYBR-Green/Rox qPCR master mix and gene specifi c primers ( • ▶ Table 2 ) (both from SABioscience, USA) according to the manufacturer's protocol. Amplifi cation of genes was performed using MX3005P (Stratagene, USA). 100 ng of cDNA was used in qPCR reaction in duplicates. The dissociation curve was checked at the end of each PCR reaction. GAPDH and β-Actin were used as housekeeping genes and for normalization. Gene expression (fold change) was calculated using ΔΔ C t method after normalizing nodular tissue with each corresponding paranodular or normal adjacent tissue.
Protein isolation and western blot
Thyrocytes cultures were rinsed twice with ice-cold PBS and lysed for 10 min on ice in lysis buff er (50 mM HEPES, 200 mM NaCl, 0.2 mM MgSO4, 0.4 mM phenylmethylsulfonyl fl uoride, 2 % Triton-X-100, 10 μg/mL leupeptine, 10 μg/mL aprotinine, 0.02 % soybean trypsin inhibitor, 0.2 mM ortho-vanadate (SigmaAldrich; Taufkirchen, Munich, Germany). Cell lysates were centrifuged for 10 min at 12 000 × g at 4 °C. Protein concentration of the supernatants was determined by Coomassie Plus protein assay kit (Pierce; Rockford, IL, USA) and were measured spectrophotometrically at 595 nm by Tecan Infi nite ® M 200 microplate reader (Tecan-Deutschland; Crailsheim, Germany). Protein was denatured in Laemmli sample buff er (Bio-Rad Laboratories; Munich, Germany) with β-mercaptoethanol (Sigma; Taufkirchen, Germany), boiled for 5 min, transferred on ice and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (50 μg per lane). PeqGold prestained protein marker IV (Peqlab Biotechnologie GmbH; Erlangen, Germany) was used as molecular weight standards. After separation, protein was transferred to a polyvinylidene difl uoride membrane (Hybond P; GE Healthcare; Munich, Germany). Blots were blocked with 10 % low-fat milk for 1 h at room temperature followed by incubation with primary antibodies from Santa Cruz Biotechnology (rabbit polyclonal VEGF [total protein], 1:200; rabbit polyclonal VEGFR-1, 1:200; mouse polyclonal VEGFR-2, clone A-3, 1:200 and mouse monoclonal β Actin, clone AC-15, 1:1 000; Sigma) overnight at 4 °C. Blots were then washed 3 × with Towbin buff er with 0.5 % Tween 20 followed by incubation for 30 min with secondary antibody from Millipore GmbH; Schwalbach/Ts, Germany (polyclonal goat antirabbit IgG, 1:5 000; goat anti-mouse IgG, 1:5 000, both HRP conjugated) at room temperature. All antibodies were diluted in Towbin Buff er with 0.5 % Tween 20 and 0.5 % bovine serum albumin. Blots were then washed and incubated with ECL (Enhanced Chemiluminescence-ECL detection kit from GE Healthcare; Munich, Germany) and exposed to ECL Hyperfi lm (GE healthcare), developed in Curix 60 (Agfa;
Dusseldorf, Germany) and documented by Gel Doc 100. β Actin was used as loading control.
ELISA
Cell culture supernatant was quantifi ed using VEGF ELISA-kit (R&D systems; Wiesbaden-Nordenstadt, Germany 
Statistical analysis
Data were analyzed using commercially available software Bias for Windows, Version 8.3.7 (H. Ackermann, Johann-Wolfgang Goethe University, Department of Mathematics). Data are presented as means ± SEM. Non-parametric tests were used due to irregularly distributed data. The groups were compared using Kruskal-Wallis'test. Paired data (nodular and paranodular tissue) were analyzed using Wilcoxon's test. Statistical signifi cance was achieved at p < 0.05.
Results
▼
Characterization of thyrocyte cultures
The primary cell cultures showed the typical morphology of thyrocytes on microscopic examination, i. e., small, elongated cells arranged as cellular isles ( • ▶ Fig. 1a, b ).
Immunohistochemical staining demonstrated the cells to be positive for cytokeratin 18 ( • ▶ Fig. 1c, d ) and so to be of epithelial origin. The cells were negative for cytokeratin 19, including fi broblasts specifi c antigen and Factor VIII (von Willebrand factor), showing no contamination of stromal and endothelial cells, yielding primary thyrocyte culture purity of greater than 98 %. In addition, using RT-PCR all cell cultures were positive for thyroid peroxidase (TPO), TSH receptor (TSHR) and thyreoglobuline (Tg), namely indicating the presence of thyrocytes ( • ▶ Fig. 1e ). Fig. 2a ) and recurrent Fig. 2c ).
mRNA expression of VEGF-A, VEGFR-1 and -2 in human thyrocytes
In Graves' disease we found the highest levels of VEGF 145 , VEGFR-1 and -2 mRNA compared to the paranodular tissue of the other 3 groups, but without reaching statistical signifi cance ( • ▶ Fig. 2d ).
Interestingly, in tissue from patients with multinodular goiter we did not fi nd any signifi cant diff erence in the expression levels of VEGF and its receptors between nodular and paranodular tissue ( • ▶ Fig. 2b ).
The results of RT-PCR were confi rmed by performing QPCR. The results are presented as fold change after normalizing nodular tissue with each corresponding paranodular tissue ( • ▶ Table 3a ) , as well as after normalizing paranodular tissue of Graves' disease with paranodular tissue of the other 3 groups ( • ▶ Table 3b ).
Protein expression of VEGF (total), VEGFR-1 and -2 in human thyrocytes
The VEGF protein was highly expressed in all cell cultures obtained. Furthermore, expression of the receptor proteins was demonstrated in over 90 % of the isolated thyrocytes. In uninodular and recurrent goiter, protein expression of VEGF was higher in nodular compared to paranodular tissue as shown in • ▶ Fig. 3a .
The same results were detected for protein expression of VEGFR-1 and VEGFR-2 ( • ▶ Fig. 3a ).
Interestingly, again in multinodular goiter we could not fi nd any diff erence in protein expression between paranodular and nodular tissue as seen at mRNA level ( • ▶ Fig. 3a ) . . 3b ).
Secretion of VEGF by human thyrocytes
All primary cell cultures secreted VEGF protein in the supernatant. The secretion level of VEGF was higher in nodular tissue of patients with recurrent goiter compared to paranodular tissue, without reaching statistical signifi cance ( • ▶ Fig. 4 ) . Again, the highest levels of VEGF were measured in tissue obtained from Graves' disease patients.
Discussion
▼ VEGF, as an angiogenic factor, has been implicated in tumor angiogenesis and in progression of diff erent malignant tumors. Therefore, it is important to investigate its role in thyroid cancer. So far, elevated VEGF expression seems to be associated with higher risk of metastasis, of recurrence and with a poor outcome in thyroid cancer [ 26 ] .
To date, the expression of VEGF in normal thyroid tissue and its role in the development of goiter and Graves' disease is not well determined.
In the present study, we were able to demonstrate co-expression of VEGF and its receptors VEGFR-1 and -2 in normal human thyrocytes and in benign diseases of the thyroid. In addition, we detected active secretion of VEGF protein by thyrocytes in the supernatant and measured higher concentrations of VEGF protein in nodular tissue of uninodular and recurrent goiter compared to the corresponding normal tissue. Furthermore, the present data demonstrate large amount of VEGF protein in nodular and paranodular tissue of multinodular goiter, that might contribute to the proliferating eff ect on thyrocytes and its involvement in goiter development. These fi ndings contradict previous studies, which reported weak expression of VEGF in benign nodules of the thyroid with no diff erences between normal thyroid tissue and benign adenomas [ 27 , 28 ] . Itoh et al. did not even fi nd any expression of VEGF in normal thyroid tissue and only negative or weak expression in adenomatous goiter [ 29 ] . These discrepancies may be explained by the methodological approach used. In previous studies, fresh frozen tissue or formalin-fi xed paraffi n-embedded tissue was primarily used for the investigation while our study examined pure cultures of freshly isolated thyrocytes, thus, excluding possible endothelial contamination and antigen masking of targets of interest due to formalin-fi xation.
With regards to the expression of the VEGF receptors, only immunohistochemistry staining of VEGF receptors expression on human thyrocytes of benign thyroid diseases has been shown so far. Jebreel et al. reported no diff erences in VEGFR-1 and -2 expression between the diff erent thyroid pathologies, so the author suggested that up-regulation of VEGF and not of its receptors was important in the development of thyroid diseases [ 30 ] . In contrast to our fi ndings, we demonstrated signifi cantly higher expression of the 2 receptors in nodular tissue of uninodular and recurrent goiter compared to corresponding normal tissue both in mRNA and protein level. These results might indicate, that not only up-regulation of VEGF, but also up-regulation of its receptors plays a critical role in the development of goiter. In addition to receptor expression, we were able to detect significant amount of VEGF in the supernatant of thyrocytes culture.
Consistent with our data, Sato et al. reported high levels of VEGF in cyst fl uid of thyroid nodules. They postulated that VEGF was secreted by thyrocytes and that it was involved in the pathogenesis of cyst fl uid accumulation [ 31 ] .
In the present study, we were able to detect an active secretion of VEGF by human thyrocytes and simultaneous expression of both VEGF receptors. This coexpression of VEGF and its receptors raises the possibility that VEGF may act in an autocrine loop in thyrocytes, as observed previously in thyroid cancer [ 32 ] . Perhaps, an autocrine stimulation plays a crucial role in proliferation of thyrocytes and such up-regulation of the VEGF signaling might be involved in the development of nodular goiter. Besides, high levels of VEGF and its receptors in recurrent nodules may pose potential risk for the development of goiter recurrence.
It is also known, that autocrine stimulation of VEGF receptors leads to enhanced tumor growth [ 33 ] . This mechanism, initiated by increased VEGF expression, may also be involved in the growth of thyroid nodules and goiter recurrence.
In our study, we did not fi nd any diff erences in gene or protein expression of VEGF and its receptors between nodular and paranodular tissue of patients with multinodular goiter, but instead detected an increased concentrations of the growth factor in both tissues. Therefore, we postulated, that in multinodular goiter the entire tissue of the thyroid gland might be pathologically altered and are not only limited in the circumscribed nodules. Although the cause of recurrence might be of multifactorial origin, elevated expression of VEGF and its receptors might also contribute to the high rate of recurrence of over 20 % of multinodular goiter after subtotal resection [ 34 -36 ] , Our fi ndings are also in accord with clinical studies which assumed an involvement of the whole thyroid parenchyma in benign disease and therefore, recommended total thyroidectomy as a suitable treatment [ 37 ] . Furthermore, we examined tissue from 10 patients with Graves' disease. In the literature, contradictory data are reported on VEGF expression in this autoimmune disease of the thyroid gland. However, several authors could not detect any expression of VEGF in Graves' disease in immunohistochemical staining [ 29 ] or only at lower levels compared to neoplastic tissue [ 30 ] and so argued that VEGF signaling plays only a minor role in the development of autoimmune disease of the thyroid gland. On the other hand, Iitaka et al. reported increased serum VEGF levels in patients with Graves' disease compared to healthy persons [ 38 ] . Furthermore, studies demonstrated a positive correlation between VEGF levels and increased vascular density in Graves' disease [ 39 ] as well as strong expression of VEGF in hyperplastic follicular cells and surrounding capillaries [ 40 ] , indicating a link between epithelial function and microcirculation. In concordance with these data, we have detected in our study high levels of VEGF and its receptors both in mRNA and protein in monocultures of thyrocytes obtained from patients with Graves' disease. Here, we have shown that the expression was signifi cantly increased compared with the other groups. These results may indicate that VEGF is involved in the pathogenesis of Graves' disease and may have an infl uence on both epithelial proliferation and thyroid microcirculation, causing a typical hypervascularization and hyperplasia seen in this autoimmune disease. Moreover, this might be a fi rst hint, that VEGF might also be involved in the control of thyroid function.
Besides the up-regulation of VEGF in goiter, the present study was able to confi rm the expression of VEGF and its receptors in Recurrent goitre Graves' disease normal thyroid tissue. Clinical studies have also reported, that over 40 % of patients treated with tyrosine kinase inhibitors (TKI) developed hypothyroidism [ 24 , 25 ] . Recently Sato et al. reported a sonographically detectable atrophy of the thyroid gland caused by sunitinib therapy [ 41 ] . One hypothesis for TKIrelated hypothyroidism is inhibition of the VEGF-pathway resulting in reduction of capillary blood fl ow. These observations and data may signify that VEGF signaling might participate not only in thyroid hyperplasia but is also essential in normal thyroid function as well as physiological proliferation of thyrocytes.
Conclusion
▼
In summary, our study showed an increased expression of VEGF and its receptors in nodular tissue of uninodular and recurrent goiter as well as in the entire tissue of multinodular goiter and Graves' disease. Therefore, we hypothesized that VEGF may be involved in the proliferation of thyrocytes and its up-regulation via autocrine mechanism might contribute to the development of thyroid nodules and hyperplasia of the thyroid gland. Although, it is very likely that goiter recurrence is of multifactorial origin, VEGF may serve as a proliferation marker in thyroid disease and may be used as a possible target for future strategies for the treatment of neoplastic and autoimmune diseases of the thyroid. Until now, the exact role of VEGF in thyroid function remains to be determined. Hence, more future studies are eminent to elucidate the role of VEGF in thyroid diseases.
Confl ict of interest:
None.
